Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the immunisation safeguards at-risk babies

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”

The pregnancy vaccine functions by stimulating the mother’s immune system to generate defence proteins, which are then passed to the developing baby through the placenta. This maternal immunity provides newborns with instant defence from the point of delivery, precisely when they are most vulnerable to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still provide meaningful protection, with evidence suggesting that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst observing that protection can still occur even if administered later in the third trimester.

• Nearly 85% coverage when immunised 4 weeks before birth
• Maternal antibodies passed through the placenta protect newborns from birth
• Protection possible with 2-week gap before premature birth
• Vaccination during the third trimester still provides significant protection for infants

Strong evidence from the latest research

The efficacy of the RSV vaccine administered during pregnancy has been established through a extensive research programme conducted across England, examining data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that half-year window, providing strong and reliable data of the vaccine’s actual performance. The study’s conclusions have been validated by the UK Health Security Agency as showing robust protection for newborns during their most vulnerable early months. The breadth of this investigation offers healthcare professionals and prospective parents with confidence in the vaccine’s established performance across different groups and contexts.

The results reveal a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were treated in hospital with RSV during the study period, with the vast majority being infants whose mothers did not receive the vaccination. This marked difference emphasises the vaccine’s vital importance in reducing the risk of serious illness in newborns. The decrease in hospital admissions above 80 per cent represents a major public health success, helping to prevent thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.

Study methodology and scope

The research analysed birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection levels and hospital admissions. The large sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and reflective of the wider population, rather than isolated cases or limited subgroups.

The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology measured real-world outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine functions when administered across diverse clinical settings and patient circumstances throughout pregnancy’s final trimester.

Grasping RSV and its hazards

Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.

The infection produces inflammation deep within the lungs and airways, making it extremely challenging for vulnerable newborns to breathe and feed adequately. Parents often witness their babies fighting for breath, their chests heaving as they work to get adequate oxygen into their damaged lungs. Whilst the majority of babies recover with supportive care, a small but significant group succumb from RSV complications each year, making vaccination as prevention a essential public health objective for safeguarding the youngest and most at-risk people in our communities.

• RSV triggers inflammation in lungs, resulting in severe breathing difficulties in babies
• Approximately half of newborns acquire the infection during their first few months alive
• Symptoms range from minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
• More than 20,000 UK infants need serious hospital treatment for RSV each year
• A small number of babies die from RSV complications annually in the UK

Adoption rates and specialist advice

Since the RSV vaccine programme launched in 2024, health officials have stressed the significance of pregnant women getting their jab at the ideal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing matters greatly for ensuring newborns receive the maximum immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery delivers approximately 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies via the placenta.

The communication from health authorities remains clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has reassured expectant mothers that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a fourteen-day window for those giving birth ahead of schedule. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst maintaining strong safeguarding for vulnerable newborns during their most critical early months when RSV poses the greatest risk of severe infection.

Regional differences in immunisation

Whilst the RSV vaccine programme has been launched across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Some areas have attained greater immunisation rates among eligible pregnant women, whilst others continue working to boost understanding and access to the jab. These geographical variations reflect variations in healthcare infrastructure, engagement approaches, and local engagement efforts, though the national data demonstrates robust and reliable protection irrespective of geographical location.

• NHS trusts launching multiple messaging strategies to reach women during pregnancy
• Regional disparities in immunisation take-up throughout England necessitate strategic intervention
• Community health services adapting programmes to align with local requirements and situations

Practical implications and parent viewpoints

The vaccine’s remarkable effectiveness translates into concrete gains for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the launch of this protective measure, the 80% decrease in admissions equates to thousands of infants protected against severe infection. Parents no more face the troubling prospect of seeing their babies labour to breathe or struggle to eat, symptoms that define critical RSV illness. The vaccine has fundamentally shifted the landscape of neonatal breathing health, offering expectant mothers a preventative option to protect their most vulnerable children during those critical early months.

For families like that of Malachi, whose serious RSV infection resulted in severe brain damage, the vaccine’s availability carries profound emotional significance. His mother’s support of the jab emphasises the profound consequences that preventable illness can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to pregnant women during their final trimester, changing what was once an unavoidable seasonal threat into a manageable health risk.